ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Therapeutic Potential of Lipid Nanoparticle-Encapsulated CD19-Targeting mRNAs in Lupus and Rheumatoid Arthritis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Anti-CD19-engineered exosomes enable B cell-targeted anti-BAFF mRNA delivery to alleviate lupus progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory Diseases.Biomedicines · 2026Review
- T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy.Biomarker research · 2026Article
- Nanotechnology-driven strategies for gene therapy of arthritis.Materials today. Bio · 2025Review
- Therapeutic Potential of Lipid Nanoparticle-Encapsulated CD19-Targeting mRNAs in Lupus and Rheumatoid Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The hyperactivation of autoreactive B cells and plasma cells leads to the development of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), therefore, targeting the abnormal B cells and plasma cells might hold promise for the treatment of these refractory and relapsing diseases. This study developed lipid nanoparticle-encapsulated mRNA-encoding antibodies (mRNab-LNPs) targeting CD19, and evaluated their therapeutic efficacy in lupus and RA mice. mRNab-LNPs enabled robust production of anti-CD19 antibodies in multiple cell lines in vitro. Interestingly, intramuscular injection of mRNab-LNPs resulted in high and sustained production of anti-CD19 antibodies in mice. In particular, the numbers of CD19+ circulating B cells and tissue-resident plasma cells are significantly reduced by mRNab-LNPs in mice. As a result, mRNab-LNPs significantly reduced the histopathological changes and tissue injuries in both lupus and RA mice. Collectively, these findings demonstrate the therapeutic and translational potential of mRNab-LNPs in the treatment of SLE and RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.